AngioDynamics Timeline

The company is organized in the state of Delaware under the name A.D. Inc. and as a wholly owned subsidiary of E-Z-EM.

Eamonn P. Hobbs becomes president and chief executive officer of AngioDynamics.

AngioDynamics common stock is added to the Russell 3000^® index and the new Russell Microcap™ Index following Russell Investment Group’s reconstitution of its family of U.S. indices.

Total Abscession – a general drainage catheter designed to percutaneously
drain abscesses and other fluid collections – is launched. It features the tamper-resistant  Vault^® locking mechanism. This unique feature eliminates additional procedures to replace drainage catheters when the locking pigtail shape becomes unlocked during routine catheter maintenance. The Vault locking mechanism reduces physician time and increases patient comfort.

AngioDynamics is named to Business Week’s list of 100 Hot Growth Companies.

The Morpheus CT PICC insertion kit is launched nationwide. Use of the kit allows the AngioDynamics proprietary peripherally inserted central catheter (PICC) to be inserted at a patient’s bedside, instead of in the interventional radiology suite at the hospital, which is the current practice.

The follow-on public offering of AngioDynamics shares of common stock is completed.

AngioDynamics announces a facility expansion at the company’s Queensbury, N.Y., U.S., headquarters, consisting of a 36,000-square-foot warehouse and distribution center to accommodate its increasing number of employees and provide a foundation for future growth of the organization.

AngioDynamics enters into a stock purchase agreement with Oncobionic Inc.

AngioDynamics is recognized as No. 11 on the Forbes 200 Best Small Companies in America list.

AngioDynamics announces the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Oncobionic Inc. to market irreversible electroporation (IRE) – a technology indicated for surgical ablation of soft tissue, including cardiac and smooth muscle.

AngioDynamics and RITA Medical System Inc. – a respected provider of medical oncology devices – announce the signing of a definitive agreement whereby AngioDynamics will acquire RITA.

AngioDynamics completes the acquisition of RITA Medical Systems. The acquisition includes facilities in California and Georgia, increases the company’s total number of employees from around 200 to nearly 550 and gives AngioDynamics immediate access to the burgeoning interventional oncology market through RITA’s specialized sales force.

RITA^® UniBlate™ RFA Electrode – a scalable, single-needle radiofrequency ablation electrode used to coagulate lesions during percutaneous, laparoscopic and intraoperative surgical procedures – is launched.

Vincent Bucci is elected chairman of the AngioDynamics Board of Directors. Mr. Bucci joined the AngioDynamics Board in January 2007 when AngioDynamics acquired RITA Medical Systems; he had been Chairman of the RITA Medical Systems Board since 2003 and a Board member since 1994.

AngioDynamics employees celebrate the company’s 20th Anniversary.

Irreversible electroporation (IRE) technology is successfully used in the first human clinical trial for the treatment of soft tissue.

AngioDynamics announces it has entered into an asset purchase agreements with Diomed Holdings Inc., Diomed Inc. and Diomed Limited for the acquisition of certain assets of Diomed’s business in the United States and United Kingdom.

Following the successful initial use of Oncobionic’s IRE technology, AngioDynamics completes the acquisition of Oncobionic Inc. per the terms of the Oct. 12, 2006, agreement.

The acquisition of certain U.S. and U.K. assets of Diomed Ltd. Is completed, substantially strengthening the AngioDynamics’ position in the market for the treatment of varicose veins.

AngioDynamics reorganizes into three business units – Peripheral Vascular, Access and Oncology/Surgery – to better serve its customers.

The VenaCure EVLT System, a new varicose vein therapy brand, is launched at the American College of Phlebology (ACP) 22nd Annual Congress. The new brand encompasses the best of AngioDynamics’ VenaCure^® product line, as well as the EVLT^® procedure, a product line which AngioDynamics had recently rescued from the bankruptcy of Diomed Inc.

The first percutaneous uses of IRE technology on liver and kidney lesions were conducted at The Alfred in Melbourne, Australia. Using AngioDynamics’ NanoKnife^TM system, Dr. Ken Thomson, Professor and Director of the Department of Radiology at The Alfred, Monash University, performed a kidney case and two liver cases.

AngioDynamics announces the implementation of a leadership development plan combining succession planning with senior management team expansion. President and CEO Eamonn P. Hobbs announces he will be stepping down when a successor is identified.

Jan Keltjens, an executive with more than 20 years of successful medical industry leadership experience, is appointed President and CEO of AngioDynamics.

The StarBurst^® XLi-Enhanced Semi-Flex probe is the first radiofrequency ablation (RFA) device specifically designed to deliver a 7cm ablation of a tumor in a single placement during Computed Tomography-aided procedures.

AngioDynamics introduces the DuraMax stepped chronic dialysis catheter at the 2009 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Scientific Meeting, held in Lisbon, Portugal. The new catheter employs Curved Tip™ Catheter Technology that is designed to provide higher blood flow and lower recirculation, even if the catheter becomes positioned against a blood vessel wall. This design approach eliminates the need for side holes common in other catheters, reducing the potential for clots.